Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quilizumab in Inadequately Controlled Allergic Asthma
NCT01582503Phase 2Completed
- Sponsor
- Genentech
- Start
- Apr 2012
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of quilizumab in allergic asthma, sponsored by Genentech. Started Apr 2012; status: completed.
02
Drugs
quilizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT01582503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01582503.